IPM Take
The sharp signal is that health AI is moving from experimentation into accountability. Medical AI systems can no longer be discussed only as innovation tools. They are becoming regulated infrastructure that must prove safety, transparency, data quality, human oversight and clinical value. For IPM, the key access question is whether smaller hospitals, weaker data systems and less-resourced countries can meet the same implementation standard, or whether trustworthy AI becomes another advantage for already advanced centres.
Executive Summary
The European Commission states that the EU AI Act entered into force on 1 August 2024 and that high-risk AI systems, including AI-based software intended for medical purposes, must comply with requirements such as risk mitigation, high-quality datasets, clear user information and human oversight. A 2026 WHO Europe report assesses AI readiness across EU health systems, drawing on a 2024 to 2025 survey of EU Member States. The report focuses on governance, legal and ethical frameworks, workforce readiness, data governance, stakeholder engagement and private-sector involvement.
Why it matters
- Policymakers: Need to make AI readiness part of health-system planning, not only digital innovation strategy.
- Hospitals / providers: Must prepare validation, procurement, workflow integration, data governance, cybersecurity and clinical oversight before adopting AI tools.
- Patients / advocates: Should expect transparency, safety monitoring and accountability when AI systems influence diagnosis, triage, treatment or access.
